EUVIMEDEUVIMED entdecken
Crossref

Rise and fall of 17 alfa-hydroxyprogesteronecaproate

Nefise Nazlı Yenigül, Berna Dilbaz

Journal of Controversies in Obstetrics & Gynecology and Pediatrics · 2023

DOI: 10.51271/jcogp-0017 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Controversies in Obstetrics & Gynecology and Pediatrics, 2023. Verfasst von Nefise Nazlı Yenigül und 1 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

17 alpha-hydroxyprogesteronecaproate (17-OHPC), a syntheticprogestogen, wasfirstapproved in 1956 totreat a variety of gynecological and obstetric conditions in pregnantwomen, includingthreatenedabortion and preterm birth. Itwaswidelyprescribedtopregnantwomen in the USA and Europe in the 1950s and 1960s. Studiesover time haveshownthat it is not successful in thisgroup of patients. Additionally, comparedtotheoffsprings not exposedto 17-OHPC, offspringsexposed had an increased risk of anycancer.

Zitieren

APA

Yenigül, N. N., & Dilbaz, B. (2023). Rise and fall of 17 alfa-hydroxyprogesteronecaproate. Journal of Controversies in Obstetrics & Gynecology and Pediatrics. https://doi.org/10.51271/jcogp-0017

Vancouver

Yenigül NN, Dilbaz B. Rise and fall of 17 alfa-hydroxyprogesteronecaproate. Journal of Controversies in Obstetrics & Gynecology and Pediatrics. 2023. doi:10.51271/jcogp-0017

BibTeX
@article{Yenigl2023,
  author = {Yenigül, Nefise Nazlı and Dilbaz, Berna},
  title = {Rise and fall of 17 alfa-hydroxyprogesteronecaproate},
  journal = {Journal of Controversies in Obstetrics & Gynecology and Pediatrics},
  year = {2023},
  doi = {10.51271/jcogp-0017}
}
Kostenlos starten →